In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Gain Therapeutics (GANX – Research Report), with a price target of $10.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thomas Shrader has given his Buy rating due to a combination of factors surrounding Gain Therapeutics’ promising developments. The company is set to release cerebrospinal fluid (CSF) data on key biomarkers, which is a significant milestone as it demonstrates the drug’s activity once it reaches its target. This data is crucial for potential partners, as it indicates how effectively and safely the drug can be delivered into the CSF.
Moreover, the ongoing trial has shown that the drug is safe in healthy volunteers, and the upcoming readouts are expected to provide insights into its efficacy in patients with Parkinson’s Disease (PD). The trial aims to include patients with genetically low levels of the GCase enzyme and those with idiopathic PD, with the potential for the drug to clear aggregated substrates in lysosomes. This could lead to significant changes in biomarkers, reflecting the drug’s impact on peripheral cells and its entry into the central nervous system. These developments, along with a thorough pre-clinical evaluation, support the positive outlook for Gain Therapeutics.
According to TipRanks, Shrader is an analyst with an average return of -1.2% and a 33.81% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Novavax, Aldeyra Therapeutics, and NRX Pharmaceuticals.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.